Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
Discontinued
Reference number: GID-TA10271
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score.
For information, the company have advised that the Committee for Medicinal Products for Human Use have not recommended an indication expansion based on the clinical trial KEYNOTE-042 at this time and therefore company will not be pursuing a licence extension with the European Medicines Agency. Therefore this appraisal will remain suspended from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.